| Myocardial Infarction
Kerendia vs Praluent
Side-by-side clinical, coverage, and cost comparison for myocardial infarction.Deep comparison between: Kerendia vs Praluent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPraluent has a higher rate of injection site reactions vs Kerendia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Praluent but not Kerendia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kerendia
Praluent
At A Glance
Oral
Once daily
Mineralocorticoid receptor antagonist
SC injection
Every 2-4 weeks
PCSK9 inhibitor
Indications
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Chronic kidney disease stage 5
- Myocardial Infarction
- Myocardial Infarction
- Coronary heart disease
- Cerebrovascular accident
- Angina, Unstable
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
Dosing
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Contraindications
- Hypersensitivity to any component of Kerendia
- Concomitant treatment with strong CYP3A4 inhibitors
- Adrenal insufficiency
- Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
Adverse Reactions
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Pharmacology
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kerendia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
Praluent
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Kerendia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Praluent
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Kerendia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Praluent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Bayer US Patient Assistance Foundation - KerendiaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$50/momo
MyPraluent Copay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KerendiaView full Kerendia profile
PraluentView full Praluent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.